Adage Capital Partners GP L.L.C. Cuts Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Adage Capital Partners GP L.L.C. reduced its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 65.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 480,000 shares of the company's stock after selling 894,000 shares during the period. Adage Capital Partners GP L.L.C. owned approximately 0.76% of Vera Therapeutics worth $20,299,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. SG Americas Securities LLC lifted its holdings in shares of Vera Therapeutics by 116.7% during the 4th quarter. SG Americas Securities LLC now owns 20,270 shares of the company's stock worth $857,000 after acquiring an additional 10,916 shares during the period. Lord Abbett & CO. LLC raised its holdings in shares of Vera Therapeutics by 41.1% during the 3rd quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company's stock worth $18,830,000 after buying an additional 124,197 shares in the last quarter. Barclays PLC lifted its position in shares of Vera Therapeutics by 94.1% during the 3rd quarter. Barclays PLC now owns 85,395 shares of the company's stock worth $3,774,000 after buying an additional 41,394 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Vera Therapeutics in the fourth quarter valued at about $2,948,000. Finally, Victory Capital Management Inc. grew its position in Vera Therapeutics by 515.0% in the fourth quarter. Victory Capital Management Inc. now owns 235,267 shares of the company's stock valued at $9,949,000 after acquiring an additional 197,014 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company's stock.

Vera Therapeutics Stock Up 1.6 %

NASDAQ:VERA traded up $0.38 during trading hours on Thursday, reaching $23.75. The company had a trading volume of 1,925,097 shares, compared to its average volume of 907,466. The business's 50-day simple moving average is $24.93 and its two-hundred day simple moving average is $35.56. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -9.10 and a beta of 1.28. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11. On average, equities analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Wolfe Research assumed coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price target on the stock. The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $58.00 price target for the company. JPMorgan Chase & Co. reduced their price objective on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 4th. Finally, Guggenheim increased their target price on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $64.67.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.